Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Hovione plans to install a $35 million ConsiGma CDC Flex line at its East Windsor, New Jersey, campus, with commissioning expected in late 2027. The system will link spray-dried amorphous solid dispersions to tablet production under one quality system. Planned continuous and batch modes span 1 to 200 kilograms per hour, with development possible using 1.5 kilograms.
This study applied multidimensional electron diffraction to cabotegravir nanocrystals within a long-acting injectable formulation. 3D electron diffraction confirmed a structure consistent with the known X-ray model, while imaging and diffraction linked particle shape to crystal structure and revealed dislocations. The results describe nanoscale structural features that may guide formulation work; improved product performance was not demonstrated.
Synthego and Biomay announced a nonexclusive North American marketing and resale collaboration covering CRISPR components and manufacturing services. The offering combines Synthego guide RNA expertise with Biomay’s Cas9, mRNA manufacturing, LNP formulation, and aseptic fill-finish capabilities, including research and cGMP options. This is a commercial supply collaboration rather than a new factory opening or a new medicine approval.
A medicinal-chemistry study developed a chiral quinazoline-based Nav1.7 inhibitor and used MicroED to confirm the lead compound’s absolute configuration. The report combined structure–activity studies with pharmacokinetic and pain-model experiments in rodents. Its pharmaceutical relevance is the stereochemical assignment within a drug-discovery program; the animal findings do not establish analgesic efficacy or safety in patients.
Cyprumed announced that MSD initiated a Phase 1 trial using its licensed oral tablet technology, triggering a milestone payment. The candidate and its structural class were undisclosed, so the program cannot be identified as a cyclic peptide. The earlier agreement’s potential $493 million comprises upfront and milestone payments, rather than cash already received. This is included as a delivery-platform reference.
Bio Farma selected Quantoom’s Ntensify platform for Indonesian mRNA vaccine development and completed an initial RNA production run in Bandung using a rabies DNA template. Quantoom reported that the 200 mL in vitro transcription run met predefined criteria. CEPI partly supported platform installation. The milestone concerns manufacturing capability building, not demonstrated vaccine efficacy or authorization for commercial product release.
This review evaluates electrophoresis, chromatography, sequencing, and mass spectrometry for measuring mRNA drug-substance identity, length, concentration, intactness, and purity. It compares throughput, sample preparation, and total analysis time while considering multi-attribute methods used for protein therapeutics. The authors identify opportunities for integrated mRNA analytics, rather than validating a universal platform that replaces all individual quality assays.
4basebio announced clinical-grade enzymatic opDNA starting-material supply for an unnamed multinational pharmaceutical company’s cell therapy program. TriLink was selected as the mRNA development and manufacturing partner, using its CleanCap technology. The collaboration supports an upcoming Phase I program and illustrates coordination between DNA template and mRNA suppliers. The customer and financial terms were undisclosed; no clinical outcomes were reported.
The AGENT platform combines Bayesian optimization with high-throughput experiments to identify thermostable mRNA-LNP formulations through six iterations in approximately one month. Solid-state model formulations based on SM-102 and ALC-0315 retained biological activity after more than two months at 37°C. Animal immunogenicity supported further development, but these formulation-specific findings do not eliminate cold-chain requirements for mRNA products generally.
Using a common ALC-0315 formulation, the study compared reporter expression from conventional mRNA, self-amplifying RNA, and plasmid DNA, individually and in combinations. Mouse experiments showed distinct timing and duration associated with payload identity. Mixed preparations generally behaved additively under the tested conditions. The work helps separate cargo effects from formulation effects, without establishing universal expression profiles across doses, tissues, or products.
Investigators administered nanoparticles to several gastrointestinal submucosal sites to examine route-dependent targeting. Gastric delivery increased pancreatic exposure in rodents, while GLP-1 mRNA improved glucose regulation in mice. Buccal administration supported local and lymphatic targeting with vaccine responses. These are tissue-directed administration experiments; they do not establish that conventional swallowed nanoparticles can survive digestion and reproduce the same delivery profile.
A lipid screen explicitly incorporated a large base-editor transcript rather than relying on small reporter RNA. The lead lipid retained favorable RNA interactions and membrane-disrupting structure as cargo size increased. It improved editing in liver, brain, and lung using different administration routes, including intrathecal and intratracheal dosing. The findings do not establish systemic delivery to all three organs.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
